AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. [electronic resource]
Producer: 20130205Description: 6152-61 p. digitalISSN:- 1097-0142
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols
- Benzenesulfonates -- therapeutic use
- Biomarkers, Tumor -- metabolism
- Carcinoma, Renal Cell -- drug therapy
- Double-Blind Method
- Enzyme-Linked Immunosorbent Assay
- Female
- Follow-Up Studies
- Humans
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Neoplasm Staging
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Prognosis
- Pyridines -- therapeutic use
- Recombinant Fusion Proteins -- therapeutic use
- Sorafenib
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.